BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19338544)

  • 1. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
    Daliani DD; Tannir NM; Papandreou CN; Wang X; Swisher S; Wood CG; Swanson DA; Logothetis CJ; Jonasch E
    BJU Int; 2009 Aug; 104(4):456-60. PubMed ID: 19338544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
    Karam JA; Rini BI; Varella L; Garcia JA; Dreicer R; Choueiri TK; Jonasch E; Matin SF; Campbell SC; Wood CG; Tannir NM
    J Urol; 2011 Feb; 185(2):439-44. PubMed ID: 21167518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.
    Dragomir A; Nazha S; Wood LA; Rendon RA; Finelli A; Hansen A; So AI; Kollmannsberger C; Basappa NS; Pouliot F; Soulières D; Heng DYC; Kapoor A; Tanguay S
    Urol Oncol; 2020 Oct; 38(10):799.e1-799.e10. PubMed ID: 32778475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
    Lopez Hänninen E; Kirchner H; Atzpodien J
    J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era.
    Tornberg SV; Visapää H; Kilpeläinen TP; Taari K; Järvinen R; Erkkilä K; Nisen H; Järvinen P
    Scand J Urol; 2018; 52(5-6):419-426. PubMed ID: 30663485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
    Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-modal treatment for metastatic renal cancer: the role of surgery.
    Russo P
    World J Urol; 2010 Jun; 28(3):295-301. PubMed ID: 20364382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of the primary tumor on the long-term results of pulmonary metastasectomy for metastatic renal cell carcinoma.
    Bölükbas S; Kudelin N; Eberlein M; Fisseler-Eckhoff A; Schirren J
    Thorac Cardiovasc Surg; 2012 Sep; 60(6):390-7. PubMed ID: 22207364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].
    Schenck M; Börgermann C; Jäger T; vom Dorp F; Sperling H; Rübben H; Lümmen G
    Urologe A; 2007 May; 46(5):528-34. PubMed ID: 17356836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.
    Ornstein MC; Wood LS; Hobbs BP; Allman KD; Martin A; Bevan M; Gilligan TD; Garcia JA; Rini BI
    J Immunother Cancer; 2019 May; 7(1):127. PubMed ID: 31097024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metastasectomy in renal cell cancer after neoadjuvant therapy with multi-tyrosine kinase inhibitors].
    Firek P; Richter S; Jaekel J; Brehmer B; Heidenreich A
    Urologe A; 2012 Mar; 51(3):398-402. PubMed ID: 22113553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical treatment of atypical metastasis from renal cell carcinoma (RCC).
    Antonelli A; Arrighi N; Corti S; Legramanti S; Zanotelli T; Cozzoli A; Cunico SC; Simeone C
    BJU Int; 2012 Dec; 110(11 Pt B):E559-63. PubMed ID: 22639956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic resection for metastases from renal cancer: long term outcome after surgery and immunotherapy approach - single center experience.
    Gardini A; Morgagni P; Milandri C; Riccobon A; Ridolfi R; La Barba G; Saragoni L; Amadori D; Garcea D
    Hepatogastroenterology; 2012 May; 59(115):687-90. PubMed ID: 22469709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma.
    Steiner T; Kirchner H; Siebels M; Doehn C; Heynemann H; Varga Z; Rohde D; Schubert J; Jocham D; Stief C; Fornara P; Hofmann R; Loening S; Roigas J
    J Cancer Res Clin Oncol; 2010 Jun; 136(6):905-10. PubMed ID: 20012752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
    Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
    Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.